The image shown is for illustrative purposes only and does not represent the actual appearance of your specific compounded medication.
Tirzepatide/
Tirzepatide/Glycine/B12 is an injectable compounded medication that is designed to help support healthy blood sugar levels, appetite control, and normal inflammatory responses. It works by activating two key receptor in the body contributing to glucose control and weight management.
Tirzepatide
Glycine
Cyanocobalamin (Vitamin B12)
Suggested Dosing
Injections should be administered subcutaneously (under the skin) one time weekly. Dosing typically begins at a lower dose, suggested initiation of 20 units (0.2 mL) weekly for the first 4 weeks, then escalates according to a titration schedule:
- Weeks 1–4: Inject 20 units (0.2 mL) one time per week
- Weeks 5–8: Inject 40 units (0.4 mL) one time per week
- Weeks 9–12: Inject 70 units (0.7 mL) one time per week
- Weeks 13–16: Inject 90 units (0.9 mL) one time per week
- Weeks 17–20: Inject 120 units (1.2 mL) one time per week
- Week 21+: Inject 140 units (1.4 mL) one time per week
Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions.
IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS
This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.
This compounded preparation:
- Has not been approved by the FDA
- Has not undergone FDA review for safety, effectiveness, or quality
- Is prepared specifically for you based on your prescriber's order
- Individual outcomes may vary
Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.
This compounded medication is only available when the commercially available product is unavailable or when a prescriber determines that there is a clinically significant difference for the patient.
Medicine Information
- Helps address appetite and supports management of food cravings1
- Supports metabolic wellness and weight management1
- Supports healthy A1C levels (a marker of blood sugar control)1
- Supports insulin sensitivity1
- Aids in cardiometabolic health measures4
Potential Side Effects
- Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk
- Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions1,5
Warnings & Precautions
- Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis
- Gastric emptying may be delayed, requiring caution for procedures involving sedation or general anesthesia due to aspiration risk
- Use caution in those with a history of diabetic retinopathy5
- Avoid use during pregnancy and breastfeeding6
Contraindications
- Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2)
Drug Interactions
- Medication interactions may occur with those on insulin, oral diabetes medications, oral contraceptives, and blood thinners. Prescribers should be mindful of the impacts that delayed gastric emptying and reduced blood sugar can have with other medications.
With a once-weekly subcutaneous injection, this compound works by activating GIP and GLP-1 receptors, which are involved in regulating appetite, fullness, and blood sugar. You may notice a decrease in appetite, fewer cravings, and a feeling of fullness.1-3 These effects may support gradual, sustained weight changes when combined with healthy lifestyle modifications. The addition of glycine may help support lean muscle mass during weight changes, and the addition of cyanocobalamin (B12) may provide nutrient support.
IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS
This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.
This compounded preparation:
- Has not been approved by the FDA
- Has not undergone FDA review for safety, effectiveness, or quality
- Is prepared specifically for you based on your prescriber's order
- Individual outcomes may vary
Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.
1. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 5;27(13):4315. doi: 10.3390/molecules27134315. Erratum in: Molecules. 2025 Mar 07;30(6):1190. doi: 10.3390/molecules30061190.
2. Tirzepatide. Lexi-Drugs. UpToDate Lexidrug. Wolters Kluwer Health, Inc. Accessed May 12, 2025. https://online.lexi.com/lco/action/doc/retrieve/docid /patch_f/7224042
3. Sardar MB, Nadeem ZA, Babar M. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024 May;49(5):102489. doi: 10.1016/j.cpcardiol.2024.102489. Epub 2024 Feb 28.
4. Sardar MB, Nadeem ZA, Babar M. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024 May;49(5):102489. doi: 10.1016/j.cpcardiol.2024.102489. Epub 2024 Feb 28.
5. Caruso, I., Di Gioia, L., Di Molfetta, S. et al. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J Endocrinol Invest 47, 2671–2678 (2024). https://doi.org/10.1007/s40618-024-02441-z
6. American College of Obstetricians and Gynecologists (ACOG). Obesity in pregnancy: ACOG practice bulletin no. 230. Obstet Gynecol. 2021;137(6):e128-e144. doi:10.1097/AOG.0000000000004395
Q: How long does it take to see a potential outcome?
A: Individual responses vary, but literature suggests that observations related to hunger signals or weight management goals may be noted within weeks. Timing depends on patient physiology, medication adherence, and other individual factors.
Q: Can I use this with other medications?
A: It can be used with certain medications, but it should not be used in combination with other GLP-1 medications. Always inform your healthcare provider about all medications and supplements you're taking to address possible interactions.
Q: What if I miss an injection?
A: Contact your healthcare provider for guidance on missed doses.
